Ask AI
ProCE Banner Activity

SERENA-6 Update: Switch to Camizestrant With Continued CDK4/6 Inhibitor for Emergent ESR1 Mutations in ER+/HER2- Advanced Breast Cancer

Conference Coverage
Slideset

With longer follow-up from the phase III SERENA-6 trial, switching from an AI plus CDK4/6 inhibitor to camizestrant plus continued CDK4/6 inhibitor at ESR1m emergence and ahead of disease progression continued to demonstrate a significant improvement in PFS and significantly improved PFS2.

Released: June 30, 2026

Share

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from Lilly and Stemline Therapeutics, Inc.

Lilly

Stemline Therapeutics, Inc.

Target Audience

This activity is intended for oncologists and other healthcare professionals who care for patients with various forms of breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate cutting-edge data from breast cancer studies at ASCO 2026 and expert guidance to optimize personalized breast cancer care and improve patient outcomes

  • Utilize prognostic and predictive biomarkers to accurately identify breast cancer patients most likely to benefit from specific targeted therapies and treatment strategies

  • Interpret newly released clinical data on novel agents, updated guidelines, and emerging therapeutic approaches for breast cancer to accelerate their effective incorporation into clinical practice